Bicara Therapeutics Inc. Common Stock (BCAX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $22.68 (+0.40%), Market cap $1.33B, 52-week low–high $8.71 ~ $24.01.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Bicara Therapeutics Inc. Common Stock are updated in real time on BlackAll Trade.
Bicara Therapeutics Inc. Common Stock trades at $22.68 (+0.40%). Real-time quotes and charts are available on BlackAll Trade.
Bicara Therapeutics Inc. Common Stock has a market cap of about $1.33B.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibod